Last updated: 2026-09-24 03:04:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Atara Biotherapeutics, Inc. (ATRA) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $8.59, with a market capitalization of $94.15M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3.92 to $19.15. This page covers its latest market performance, valuation, price trends and company information.
$94.15M | |
$8.92 | |
$1,639.00 | |
$3.92 | |
$8.93 | |
39.01K | |
59.13K | |
-- | |
$19.15 | |
$3.92 | |
-- | |
-- |
Atara Biotherapeutics, Inc. (ATRA) last closed at $8.93 as of 2026-09-23 23:31:00, unchanged from the previous close of $8.93.
During the latest regular trading session, ATRA traded between $3.92 and $1,639.00, with a volume of 39.01K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Atara Biotherapeutics, Inc. (ATRA) moved from $9.25 to $8.59, representing a decline of 7.19% ($0.66).
The stock traded between $8.33 and $10.37 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 49.25 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 30.6%
ATRA is currently trading at $8.59, placing it 30.6% of the way from its 52-week low of $3.92 to its 52-week high of $19.15. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA3431, and ATA3219.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 10 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Atara Biotherapeutics, Inc. (ATRA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.